Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 20, No. 2, 2011
Issue release date: January 2011
Section title: Original Paper

Open Access Gateway

Med Princ Pract 2011;20:159–164

p53 Protein Accumulation and Presence of Visceral Metastasis Are Independent Prognostic Factors for Survival in Patients with Metastatic Inflammatory Breast Carcinoma

Sezgin C.a · Gokmen E.a · Kapkac M.b · Zekioglu O.c · Esassolak M.d · Karabulut B.a · Sanli U.A.a · Uslu R.a
Departments of aInternal Medicine (Division of Medical Oncology), bGeneral Surgery, cPathology and dRadiation Oncology, Ege University Medical Faculty, Izmir, Turkey
email Corresponding Author

Canfeza Sezgin, MD

Ege University Medical Faculty, Division of Medical Oncology

Tulay Aktas Oncology Hospital

TR–35100 Bornova/Izmir (Turkey)

Tel./Fax +90 232 374 7321, E-Mail canfeza.sezgin@ege.edu.tr

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Objective: The aim of this study was to determine the markers of prognosis in metastatic inflammatory breast cancer (IBC). Subjects and Methods: The prognostic value of patients’ clinical characteristics and expression of c-erbB-2, p53, Ki-67, ER and PgR were assessed in the 45 patients with IBC who had developed distant metastasis. Immunohistochemical methods were used to detect the expression of c-erbB-2, p53, Ki-67, ER and PgR in surgical resection specimens of the patients’ primary tumor. Results: The median overall survival (OS) measured from the diagnosis of metastatic disease was 23 months. In the univariate analysis, p53 protein accumulation and the presence of visceral metastasis were predictive of poor survival (p = 0.01 and 0.003, respectively). In the multivariate analysis, accumulation of p53 protein and the presence of visceral metastasis correlated with OS (p = 0.02 and 0.008, respectively). Conclusion: In metastatic IBC, accumulation of p53 protein and presence of visceral metastasis are independent prognostic factors for OS. Established prognostic factors in non-IBC patients such as patient age, histologic grade, hormone receptor status and c-erbB-2 status did not have independent significance in IBC in this study.

© 2011 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: December 27, 2009
Accepted: May 19, 2010
Published online: January 20, 2011
Issue release date: January 2011

Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 2

ISSN: 1011-7571 (Print)
eISSN: 1423-0151 (Online)

For additional information: http://www.karger.com/MPP

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.